News
We send the latest information from SMC Laboratories.
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in …
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of …
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…
Introduction of Chronic Kidney Disease Mice Models
I am writing you today to share some information on our chronic kidney disease (CKD) models. CKD is a c…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA,…
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For…